Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer

• Main Authors: Poh, Mau Ern, Balakrishnan, Sivasubramaniam, Tan, Sin Nee, Zainal Abidin, Muhammad 'Adil, Liam, Chong Kin, Tan, Jiunn Liang, Pang, Yong Kek, Alaga, Arvindran, Tho, Lye Mun, How, Soon Hin
• Format: Article
• Language: English; English
• Published: Society for Translational Medicine (STM), Hong Kong 2024
• Subjects: RC254 Neoplasms. Tumors. Oncology (including Cancer)
• Online Access: http://irep.iium.edu.my/113387/8/113387_Real-world%20efficacy%20of%20low%20dose%20osimertinib%20as%20second-line.pdf; http://irep.iium.edu.my/113387/14/113387_Real-world%20efficacy%20of%20low%20dose%20osimertinib%20as%20second-line_Scopus.pdf; http://irep.iium.edu.my/113387/; https://tlcr.amegroups.org/about; https://dx.doi.org/10.21037/tlcr-24-243
• Institution: Universiti Islam Antarabangsa Malaysia

Background: Response rates of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC) to lower doses of osimertinib [20 mg once daily (OD) and 40 mg OD] are similar to those of the recommended dose of 80 mg OD, but there is a lack of real-world evidence on the e...